Blenrep shows overall survival benefit in head-to-head DREAMM-7 ... - GSK
1 day ago · Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The overall survival results from the DREAMM-7 trial underscore the potential for this Blenrep combination to extend the lives of patients with relapsed/refractory multiple myeloma. This is a statistically significant and clinically meaningful advancement for ...
About multiple myeloma Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable.5,6 There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year.7 Research into new therapies is needed as multiple myeloma commonly becomes refractory to available
GSK Builds Case for Blenrep with Multiple Myeloma OS Data
1 day ago · GSK on Thursday revealed additional data from the Phase III head-to-head DREAMM-7 study, touting significantly better survival outcomes in multiple myeloma patients treated with its antibody-drug conjugate Blenrep (belantamab mafodotin) than with Johnson & Johnson’s Darzalex (daratumumab). DREAMM-7 is one of two studies—alongside DREAMM-8 ...
GSK hails survival data with revived myeloma drug Blenrep
1 day ago · GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
23 hours ago · In boost to GSK's £3B plan for Blenrep, myeloma ADC shows survival edge over J&J's Darzalex. GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears ...
DREAMM-7 phase III trial shows Blenrep combination ... - GSK
Feb 5, 2024 · The DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical development programme continues to evaluate the potential of belantamab mafodotin in early lines of treatment and in combination with novel therapies and standard of care treatments.
GSK Reports Positive Headline Results From DREAMM-7 Phase III …
1 day ago · Nov. 14, 2024, 02:30 AM. (RTTNews) - GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating ...
GSK builds case for Blenrep's return in myeloma, showdown with …
Jun 2, 2024 · GSK details Blenrep combo data that could bring the multiple myeloma ADC back to life. By a cross-trial comparison, the 48% PFS benefit seen in Blenrep’s latest DREAMM-8 study looks smaller...
GSK reports outcomes from Phase III multiple myeloma trial
13 hours ago · GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab mafodotin) along with bortezomib and dexamethasone (BorDex) for relapsed or refractory multiple myeloma as a later or second line treatment. The head-to-head, randomised, multicentre, open-label, DREAMM-7 trial assesses ...
GSK’s Blenrep combo meets key survival endpoint in Phase 3 multiple …
1 day ago · GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch ...